A previous study showed that the TP53 mutation in lung cancer might shorten the survival of patients treated with targeted therapy for oncogenic driver mutations.29MAP2K1 mutations have been shown to indicate a special subset of LUAD that might potentially benefit from MEK inhibitors.42 In our study, TP53 and MAP2K1 exhibited a highly significant pattern of concurrent mutations, which indicates that MAP2K1 is a novel target for LUAD with TP53 alterations. This evidence concerns the gene MAP2K1 and lung carcinoma.